Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adelaide A Hebert

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Dermatological Treatment|May 12, 2024
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trialsAdelaide A Hebert, Carsten Flohr, H Chih-Ho Hong, et al.
Journal of Drugs in Dermatology : JDD|December 4, 2024
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and AdolescentsLawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal AcneLeon H Kircik, Julie C Harper, Michael Gold, et al.
The Journal of Clinical and Aesthetic Dermatology|February 5, 2026
Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus PanelAngela L Rosenberg, Milaan Shah, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES StudyEmmy Graber, Hilary E Baldwin, Richard G Fried, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES StudyHilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Dermatological Treatment|May 12, 2024
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trialsAdelaide A Hebert, Carsten Flohr, H Chih-Ho Hong, et al.
Journal of Drugs in Dermatology : JDD|December 4, 2024
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and AdolescentsLawrence F Eichenfield, Adelaide A Hebert, Julie C Harper, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Safety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal AcneLeon H Kircik, Julie C Harper, Michael Gold, et al.
The Journal of Clinical and Aesthetic Dermatology|February 5, 2026
Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus PanelAngela L Rosenberg, Milaan Shah, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES StudyEmmy Graber, Hilary E Baldwin, Richard G Fried, et al.
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES StudyHilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Pageof 15